Agencourt Installs Second SOLiD; Sees Next-Gen Replacing Some Sanger Long Term | GenomeWeb
Responding to customers’ increasing appetite for next-generation sequencing, Agencourt Bioscience has acquired a second SOLiD sequencer from Applied Biosystems, the Beckman Coulter subsidiary said this week.
 
The instruments still pose challenges both on the front end and the back end but will not affect the company’s fleet of 35 Sanger sequencers in the short term, Agencourt said. However, they will probably replace some of them in the long run.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.